ClinicalTrials.gg
CompletedNCT03516630Updated Jul 31, 2020

Effects of Three Single Oral Doses of Trazodone on the QTc Interval Duration in Healthy Volunteers

A Phase 1 interventional study of Trazodone 20 mg and Trazodone 60 mg in Healthy, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 1 site in Switzerland. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-31.

Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Mar 2017, registered Apr 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

The present study has been designed to evaluate the effect of three doses of trazodone (20, 60 and 140 mg), in comparison to placebo, on the QT/QTc interval of healthy volunteers. Trazodone oral drops 6% formulation has been selected in order to evaluate the three doses using the same formulation, because the lowest available strength for the tablet formulations is 50 mg. According to the E14 guideline on the evaluation of QT/QTc interval prolongation and proarrhythmic potential of antiarrhytmic drugs, a negative control (placebo) and a positive control (moxifloxacin) will also be assessed.

Read the detailed description

Twenty (20) healthy volunteers (about 50% males and 50% females) will be randomised.

Primary end-point:

  • Evaluation of the relationship between the plasma concentration of trazodone (free base) and the change from baseline in QTc, placebo-adjusted and corrected for HR based on the Fridericia correction method (QTcF) method (∆∆QTcF).
  • Trazodone can be declared to have no influence on QTc if the null hypothesis, that the upper bound of the two-sided 90% CI of the predicted mean placebo corrected change from baseline for QTcF is greater than 10 msec at the observed mean Cmax for the therapeutic dose of trazodone, can be rejected.
02

Conditions studied

  • Healthy

Keywords

  • Trazodone
  • QTc interval
  • Moxifloxacin
03

In context

Lead sponsor

Aziende Chimiche Riunite Angelini Francesco S.p.A is the lead sponsor of 40 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Sex and Age: males/females, 20-50 years old inclusive
  • (BMI): 18.5-28 kg/m2 inclusive
  • Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89 mmHg, heart rate 50-90 bpm, measured after 5 min at rest (supine)
  • and fertility (females only): females of must be using at least one of the following reliable methods of contraception:

    1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit
    2. A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit
    3. A male sexual partner who agrees to use a male condom with spermicide
    4. A sterile sexual partner

Main Exclusion Criteria:

  • (12-leads, supine position): any of the following conditions: Heart rate \<50 or >90 bpm; PR \<120 or >200 msec; QRS >110 msec; males >430 msec, females >450 msec; Any qualitative/morphological abnormality except: sinus arrhythmia, isolated premature atrial complexes/premature ventricular complexes; T-wave/U-wave characteristics making determination of the end of the T-wave difficult such as biphasic T-waves, U-waves of width greater than 1/3 the width of the preceding T-wave
  • Diseases: history of additional risk factors for torsade de pointes (e.g. heart failure, hypokalaemia, family history of long QT syndrome); history of significant renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study
  • Medications: any medications, including over the counter (OTC) medications and herbal products, and in particular medications that prolong the QT/QTc interval and potentially hepatotoxic drugs or hepatic/gastric enzyme inducers (i.e. phenobarbital, phenitoine, carbamazepine, chlorzoxazone and rifampicin) for 2 weeks before the start of the study and during the study duration. Hormonal contraceptives for females will be allowed
  • Physical findings: abnormal physical findings
  • Laboratory analyses: clinically significant abnormal laboratory values
  • Investigative drug studies: participation in the evaluation of any product for 3 months before this study.
  • Blood donation: blood donations for 3 months before this study
  • Drug, alcohol, caffeine, tobacco: history of drug and/or alcohol dependence [alcohol abuse defined as >1 drink/day for females and >2 drinks/day for males, defined according to USDA Dietary Guidelines 2015-2020]; caffeine abuse (>5 cups coffee/tea/day) or tobacco abuse (more than 10 cigarettes/day)
  • Drug test: positive result at the drug test at screening or day -1
  • Alcohol test: positive alcohol breath test at day -1
  • Grapefruit juice: grapefruit juice consumption within 2 weeks of the administration of the study treatments
  • Pregnancy (females only): positive or missing pregnancy test at screening or day -1, pregnant or lactating women
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    TRZ 20

    Product is administered as single dose in the morning, under fasting conditions. 10 drops for the dose of 20 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.

    Drug: Trazodone 20 mg

  • Experimental
    TRZ 60

    Product is administered as single dose in the morning, under fasting conditions. 30 drops for the dose of 60 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.

    Drug: Trazodone 60 mg

  • Experimental
    TRZ 140

    Product is administered as single dose in the morning, under fasting conditions. 70 drops for the dose of 140 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.

    Drug: Trazodone 140 mg

  • Placebo comparator
    Placebo

    Product is administered as single dose in the morning, under fasting conditions. Trazodone-matching placebo corresponding to 70 drops is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.

    Drug: Placebo

  • Active comparator
    Moxifloxacin

    Product is administered as single dose in the morning, under fasting conditions. One 400 mg tablet is swallowed (without chewing) with 240 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.

    Drug: Moxifloxacin 400mg

Interventions

06

What researchers measure

Primary outcomes

  1. Relationship between trazodone plasma concentration and QTc

    Evaluation of the relationship between the plasma concentration of trazodone (free base) and the change from baseline in QTc, placebo-adjusted and corrected for HR based on the Fridericia correction method (QTcF) method (∆∆QTcF).

    Time frame: pre-dose (-0.25 hours) and at 0.0833, 0.1666, 0.3333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

  2. Influence of trazodone on QTc

    Trazodone can be declared to have no influence on QTc if the null hypothesis, that the upper bound of the two-sided 90% CI of the predicted mean placebo corrected change from baseline for QTcF is greater than 10 msec at the observed mean Cmax for the therapeutic dose of trazodone, can be rejected.

    Time frame: pre-dose (-0.25 hours) and at 0.0833, 0.1666, 0.3333, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose.

07

Study locations

1 site
  • CROSS Research S.A., Phase I Unit,
    Arzo, CH-6864, Switzerland
08

References and documents

Publications

  • Tellone V, Rosignoli MT, Picollo R, Dragone P, Del Vecchio A, Comandini A, Radicioni M, Leuratti C, Calisti F. Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. J Clin Pharmacol. 2020 Nov;60(11):1483-1495. doi: 10.1002/jcph.1640. Epub 2020 Jun 2. PubMed 32488885 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in May 2017, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2018
First posted
May 4, 2018
StartActual
Mar 20, 2017
Primary completionActual
May 1, 2017
CompletionActual
May 1, 2017
Last update
Jul 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03516630
Collaborators
Cross Research S.A., eResearch Technology, Inc.
Responsible party
Sponsor
First posted
May 4, 2018
Start date
Mar 20, 2017
Primary completion
May 1, 2017
Completion
May 1, 2017
Last update
Jul 31, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion